Advanced Technology in Wound Healing
1 Year Subscription
Author: John S. Steinberg, DPM, FACFAS
Associate Professor, Department of Plastic Surgery
Georgetown University School of Medicine
Lets go real quick into advanced technology and wound heeling. What I want to accomplish here is to give you some ideas on what we do and how we do it and how you separate these different technologies. One word of caution, this product just came out. If you get Parade Magazine in your Sunday newspaper, youll see that Cozy Toes is now available for $997, you can 50% off the actual catalogue prize, free shipping and handling. And if you look, this actually puts an end to bunions, hammertoes, toe cramps, ball of foot pain, plantar fasciitis. I mean, look at this amazing device. This picture here, bunion, hammertoe and all this pain into a foot that has sparkles on it. So if youre wondering why I do wound care, its because this product has completely ruined my reconstructive surgical business because Cozy Toes will fix everything else. So be careful about that, you may want to either sell these through your office or you may want to just buy them all up so no else can get it. These people make millions in these magazine ads with the bunion fixers and the bunion splints and the night splints in the Cozy Toes ad. Its kind of scary what kind of finances those folks make.
This is one of my patients who has a nonhealing midfoot ulceration, Charcot deformity, diabetes, neuropathy, kidney transplant, and I asked him as I was filling out his handicap parking permit, I asked him how much driving he did and he was very proud of showing me a picture of his vehicle and his motorcycle that he actually drives.
Diabetes care, March 1999 Gayle Reiber pointed out to us a very important fact of the diabetic foot and the diabetic foot ulceration, and that it is that it is very expensive to not heel a diabetic foot ulcer. You heard Bob Frykberg talk about that somewhat with us in the sessions prior, and the reality here is that in $1995, so 15 years ago, the reality is it costs $30,000 a year to not heal a foot ulcer, just to maintain it. So, the reality here is that you have to realize the fact that this is probably $60,000, $80,000, $90,000now in todays dollars and this has to be dealt with and has to be realized. This is where we talk about with the insurance companies and other payers that hey, its may be $1200 for this graft today, but were going to heel the wound in six weeks rather than have the same situation persist for three or four of a nonhealing ulcer.
Wound Bed Preparation this has become a highly academic subtopic now in the field. The concept here is that we want to actually have an optimized wound bed to receive your graft, whether its an autogenous skin graft, whether its a wound vac that youre putting on, whether its some type of a bioengineered living or nonliving tissue or scaffold, you need to optimize the wound bed to receive that, otherwise youre throwing away resources time, effort, and money.
Peter Sheehan helped us with this data and that was published in Diabetes Care in 2003, to understand that at three to four weeks if this wound is showing a nonhealing trajectory so if at four weeks you havent healed by 50% with debridement, offloading, and moist wound healing, that wound will also remain nonhealing at 12 weeks, 24 weeks, 48 weeks. We can predict these non-healers very early. So there is no need to wait three months to declare a wound to be chronic. The chronic wound can be defined that way at the three to four week range.
Bioengineered Alterative Tissues the concept here this all started with kind of Procuren and Regranex, and what were looking at is the reality that these technologies are actually interacting with the wound. And when you actually interact with the wound and change the biology of the wound when you interact with the biology of the wound, what youre actually accomplishing here is that you are actually going to change the outcome of the wound. Weve done a lot of dressings, we got a lot of topical wound care, weve got a information from previous. But, what were doing here with these categories and these products is that we actually are interacting with the wound bed itself and were creating an actual biologic stimulation to the wound bed.
So lets start out with Procuren and Regranex. Were now using these biologic scaffolds, these nonliving acellular products, weve seen a lot of this presented already. This includes items like graft jacket, Integra, Unite Biomatrix, MatriStem, Oasis. These all fit into this subcategory, and then is a final category here of the living tissues. We heard Lee Rogers talk about some of these technologies earlier, the Apligraf and the Dermagraft. These are living cell technologies where you actually are in somewhat transplanting a living human cell thats has been cultured and grown in a cell bank on to the recipient graft site of your patient.
The science here that were delivering actual cell therapy, you have a barrier function and a dermal matrix for these patients that you receive from these various products. And what this all centers around is the human fibroblast. So you have to keep in mind that this biology that were delivering from the fibroblasts is actually creating the growth factors and creating the stimulation of the wound and the healing.
Characteristics of Bi-Layer Cell Therapy highly proliferative healing capacity, production of cytokines and matrix proteins, and even producing antimicrobial peptides. So these grafts, these living tissues grafts and the fibroblasts that persist inside of them are actually producing their own antimicrobial, their protective peptides that are preventing infection of these wound beds.
This is actually a piece of Integra. The concept with Integra here is that were using this in some of these deeper tissue defects. It started off in burn patients because were trying to regenerate or replace a human dermis, and in these particular cases were actually regenerating this tissue over potentially exposed tendon, bone, capsule, and joint so that we can actually then move on to a secondary graft. So this type of a scaffolding product, that middle category, the nonliving acellulars, these are stepping stones to get to where you want to be. These are not going necessarily be the wound closure products.
The concept here in the application, as you can see, this is generally an operating room procedure if were dealing with a deep wound. Many of these can be applied at the bedside if its a superficial wound and a lot of living tissues are routinely done in the clinic for these individuals.
A couple of cases here for you to look at a patient who required a partial calcanectomy. This was actually an X-fix pin site that was neglected, went on to an infection, ended up calcaneal osteo from a pin which is fairly rare, of course, but it can happen, and in the complication of diabetes and history of Charcot foot. When we resected this, we had a large soft tissues defect. So we covered that with an Integra graft along with negative pressure wound therapy. At two weeks we removed the silicon layer of the graft and at five weeks we applied the skin graft. So moving this patient rapidly from a deep defect exposing bone, covering that bone in a couple of weeks, after the bone is covered we come behind that and put on a skin graft.
This is a patient who was transferred into Georgetown, another hospital had been working on a patient, was not responding, still had a high white count, still was having difficulty with infection, and in fact this was a dorsal and plantar I&D already done but has significant osteo with the fourth and fifth ray including abscess of the joint. So the septic joints were resected, the corresponding toes were amputated, and we reconstructed this though a ladder by using first negative pressure and appropriate antibiotics and surgical debridement. Then we move on to rebuilding the tissues and we used Integra in this particular case. We then went on to a living bioengineered tissue, in this particular case Apligraf and then follow that a couple weeks later with a skin graft. So this kind goes into the wound bed preparation. We were using all these other products as wound bed preparatory products to get us to the skin graft phase where we could actually cover and close this.
A 70-year-old gentleman whos already lost his other leg, came in with an exposed necrotic tibials anterior tendon, positive MRSA wound here at the distal TMA site. And if you look at the other aspects of the same leg, hes got a posterior heel ulcer, exposed Achilles tendon with tissues necrosis, a lateral malleolar ulcer, and a fifth met base ulcer. So this is pretty ugly when you look at this and this certainly would be a recipient for amputation. However, this patient has already lost his other leg, so in this case were actually getting and go ahead and do what we can at his discretion to try an actually salvage this extremity. So he was first admitted, Infectious Disease, revascularized by vascular surgery and then moving on to debridement by our service. So the challenge would be that if you debride the patient first without revascularizing first, you are going to end up with more necrotic tissue and a dead foot.
We moved on to a Choparts amputation. We did an Achilles tenotomy. We used a non-layered graft anteriorly, we used Integra followed by Apligraf on the posterior aspect, and we had rapid coverage and closure of this challenging problem wound. So even in some of these extreme cases we can salvage the extremity and leave the patient with at least a biologic prosthesis that they can pivot from bed to chair and from chair to commode with.
Another challenging example, this is a patient who had a crush injury. Of course, in crush injuries we have to be aware of and be mindful of compartment of syndrome, which was indeed a factor for this patient. So there was dislocation and fracturing with avulsion of the distal pulp of the toe. What youre looking at here is exposed distal phalanx bone right here. This is fasciotomy that was performed for compartment syndrome and a medial fasciotomy performed for compartment syndrome. You see this, obviously has edema continues and you leave this open for a few days, the skin will retract. We eventually brought this patient back for revision, debridement, and closure of the fasciotomies. We put some bioengineered tissue, in this case Integra, over that exposed bone in hopes that we could avoid an amputation, but I was certainly very skeptical and I was planing on doing most likely a revision to a partial hallux amputation.
The dislocation at the MPJ was managed with a MiniRail external fixator to keep that stable, and we actually got lucky on this case. We removed X-fix when the joint was stable and we just allowed this to continue to granulate in with appropriate wound care, keeping the wound environment moist and then eventually getting actual epithelization over a period of about three months.
A 49-year-old male, diabetes, history of an injury to his toe, required an amputation, and now hes got a nonhealing wound. You can see this is a fibrotic nonhealing wound base. You can see the foot itself has an atrophic appearance. We talked on Thursday afternoon about intrinsic minus. This is definitely an intrinsic minus foot. Hes got autonomic neuropathy. Allen Jacobs talked about that earlier for today that this dry peeling cracking skin, nails fungal changes, you can see the soft tissues atrophy, you can see the loss of intrinsic musculature, and in this case you can see what appears to be an ischemic foot as well.
So before you go in and play hero and debride and revise and do some type of surgery for this patient, youll obviously have to get your vascular workup, and the vascular workup for this patient was that he needed a revascularization. After that was completed, now we can come in and safely do our debridement, get down to a granular healthy wound bed, move on to tissue grafting, and eventually on to complete closure.
What I would challenge you about these two slides, in followup to the discussion about autonomic neuropathy, is that look at what the revascularization did for this patient. Now the wound healing had something to do with it, but I would give way more credit to the vascular surgeon and what they were able to do in changing this foot. Youve now got supple healthy looking skin, even got improvement, there is no more dryness, even got improving to the nails themselves looking at this in a long-term postop. So, the reality is that blood flow is, of course, in this particular patient was the rate limiting factor.
The concept here again is a stepwise approach, just like what we talked about dealing with infection on Thursday with a diabetic foot. If you are systematic about this and stepwise about it, for the boards of course you have to somewhat think about what answer is that they want me to give, because its not always necessarily what youre doing today in practice and residency, but for the most part it does make sense in conjunction with what youre doing clinically. So, think about this from a common sense perspective, be systematic about your approach to it, and realize that theyre looking for the comprehensive thought process here, not sometimes just the absolute memory of a particular fact.
Any questions you guys can think of?
|Goals and Objectives|
After participating in this activity, the viewer should be better able to:
1. Distinguish the difference between good wound care and advanced wound healing.
2. Choose when to transition from good wound care to advanced healing modalities.
3. Assess appropriate uses of advanced wound healing methods.
Estimated time to complete this activity is 22 minutes.
Physicians, diabetes educators, and other health care professionals who treat patients with diabetes.
Complete the 4 steps to earn CE/CME credit:
It is the policy of PRESENT e-Learning Systems and it's accreditors to insure balance, independence, objectivity and scientific rigor in all individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.John Steinberg, DPM has no relevant financial relationship(s) to disclose.
This web site will respect the confidentiality of the information that is transmitted on it in accordance with the provisions of this Agreement. The Web Site uses a random identifier, which is a session number attributed to the Registered User as he enters the site. This session number is expunged of the Web Site system as Registered User leaves. Please be advised that the Registered User's visit to the Web Site leaves a retrievable trace that allows the Web Site to gather raw data on the Registered User. Such technical retrieving system is necessary in order to secure the Web Site system.
This web site uses statistic and measurement systems which compile and process information such as IP numbers and number of visited pages. This information is processed in order to establish members' profiles and trends that may lead to, for example, market studies.
By registering to Web Site services, the Registered User agrees that his/her personal information may be archived in the members database of the Web Site and be used to transmit newsletters published by the Web Site and communications such as press releases or commercial information by the Host.
Information We Collect
Information We Collect from Unregistered Visitors
Visitors to each of our Web sites can access the Web site's home page and browse some areas of the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you. On most of our Web sites, you must register with us to use the entire site.
Information We Collect When You Register
Customers registering for services on our Web sites are asked to provide us with identifying information, such as name, gender, contact information, and other personal information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion. You will also be given a choice about whether or not you want to receive newsletters and other information that we distribute from time to time. This PRESENT e-Learning Systems Web site will explain how personally identifiable information will be used and ask for your consent before collecting it.
Discussion Boards: When you use a discussion board on one of our Web sites, you may post a message and your user name, which is available for all registered users to see. When you are posting publicly, any user of our Web site can see your message. You should not post any information you want or are required by law to keep private to a discussion board or other public forum on our Web sites.
My CV (Curriculum Vitae): On our web site, we offer an online data based profiling tool in which you supply information that is part of your curriculum vitae or professional resume. This tool stores the information that you provide on our servers. The information is accessible by other members and the public, and is designed to advertise you to the online community and allow other's to find you based on the information that you provide. We will always make it clear to you when information you provide to us through a tool will be saved.
Member Lookup: On our website, other members will be able to look you up and send you messages. If you opt not to be listed (blocked), no other members will be able to look you up.
In addition, we gather information about you that is automatically collected by our Web server, such as your IP address and domain name. We will use this information to personalize its offerings and presentations to you, facilitate your movements throughout our Web sites, provide personalized services, and to communicate with you individually.
Continuing Medical Education
When you register for a Continuing Medical Education ("CME") or a Continuing Education ("CE") activity through our web site, we collect certain personally identifiable information from you such as your name, email address and mailing address. We require that you provide the state in which you are licensed and your license number. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:
(i) We are accredited by the Accreditation Council for Continuing Medical Education ("ACCME") to provide continuing medical education for physicians, through a sponsorship agreement with the Mount Sinai School of Medicine. As an ACCME accredited entity, we are required periodically to submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years;
(ii) Commercial supporters of CME/CE activities on our Web site will receive only a data about CME/CE activities that are relevant to their interests and/or the courses they support;
Uses We Make of Information
We collect data about visitors to our Web sites for product development and improvement activities. We also use it for market analysis. We may provide information from our Web sites in aggregate form, with identifying information removed, to third parties. For example, we may tell a health care partner what percentage of our registered users are of a particular medical specialty or have certain credentials. Any third party that receives our data must agree not to attempt to re-identify the people it belongs to. For example, we may provide information to a potential advertiser of a product that would appeal to a diabetes patient about what percentage of our users have diabetes. Depending on our agreement with the third parties, we may or may not charge for this information.
Marketing and Advertising
We may target our advertising or marketing depending on information we have about you. For example, a user that is a healthcare professional who treats diabetes may receive advertising for new diabetes therapies (although in neither case will the advertiser have access to any individually identifiable information about you). We may also personalize our Web site based on your interests. For example, you may see different articles in different places on our Web site based on information you have shared with us, or information we have gained by observing your previous behavior, or information we may have gained from your interactions with a third party that shares information with us. We use information for our own internal marketing, research, and related purposes. Third Parties In addition to aggregate information (discussed previously), we may share some kinds of personally identifiable information with third parties as described below.
Other Companies: We have strategic relationships with other companies who offer products and services on our Web sites. When you are interacting with those companies, different rules and privacy policies may apply. We do not control the collection or use of information you provide to these companies, but we do require that those companies clearly state their policies so you can decide whether to give them any information.
Promotional Offers: Sometimes we send offers to selected groups of customers on behalf of other businesses. When we do this, we do not give that business your name and address. We provide a variety of mechanisms for you to tell us you do not want to receive such promotional offers. For example, we may provide an opt-in box for consumers to receive an email from another business, and we make clear that by opting in you are submitting your data to a third party.
Protection of Information
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. We use security methods to determine the identity of its registered users, so that appropriate rights and restrictions can be enforced for that user. Reliable verification of user identity is called authentication. We use both passwords and usernames, as well as double opt-n verification, to authenticate users. Users are responsible for maintaining their own passwords.
Access to Information and Choices
Correction of Information We Have About You
If you believe that registration information collected by our Web site(s) is in error, you may edit your personal profile any time that you like. You can directly edit most of your user profile on the Web site on which you initially registered. Information that you can not edit may only be changed by contacting Web Customer Support (see CONTACTS). Requests for deletion of your record may result in your removal from the registry, but we may keep certain demographic information about you for product improvement purposes. You may contact Web Customer Support and ask for the changes that you would like to make.
This website and its content is copyright of PRESENT eLearning Systems, LLC - © 2007-2012 All rights reserved. Any redistribution or reproduction of part or all of the contents in any form is prohibited other than the following:
You may not, except with our express written permission, distribute or commercially exploit the content. Nor may you transmit it or store it in any other website or other form of electronic retrieval system.